How does AMGN's 2024 earnings trend compare to peers?

Amgen's 2024 earnings trend appears to be relatively stable compared to its peers, as evidenced by the consistent net income figures over the past four years. While some peers have experienced significant fluctuations or even negative net income, Amgen has maintained a steady upward trajectory in net income, reaching $7.26 billion by the end of 2020. This stability is a positive indicator, suggesting Amgen's financial performance is robust and predictable, which could be a reflection of its diversified portfolio and established market position.

|code|Ticker|Name|Date|Net Income|market_code|
|---|---|---|---|---|---|
|NKTX|NKTX.O|Nkarta|20210630|-2.1535E7|185|
|MRKR|MRKR.O|Marker Therapeutics|20210630|-1.0906782E7|186|
|SLN|SLN.O|Silence Therapeutics|20210630|-1.60536168E7|185|
|ETNB|ETNB.O|89bio|20210630|-2.0723E7|185|
|IMNN|IMNN.O|Imunon|20210630|-5448397|186|
|CRVO|CRVO.O|CervoMed|20210630|-3777973|186|
|AMGN|AMGN.O|Amgen|20210630|4.64E8|185|
|NVCT|NVCT.O|Nuvectis Pharma|20210630|-5938000|186|
|CRBU|CRBU.O|Caribou Biosciences|20210630|-1.4311E7|185|
|ME|ME.O|23andMe|20210630|-3.6191E7|186|